Novel GSK-3β inhibitors from sequential virtual screening

Hye Jung Kim, Hyunah Choo, Yong Seo Cho, Kyoung Tai No, Ae Nim Pae

Research output: Contribution to journalArticlepeer-review

49 Citations (Scopus)


Glycogen synthase kinase-3 (GSK-3β) has been emerging as a key therapeutic target for type-2 diabetics, Alzheimer's disease, cancer, and chronic inflammation. For the purpose of finding biologically active and novel compounds and providing new idea for drug-design, we performed virtual screening using commercially available database. Three-dimensional common feature pharmacophore model was developed by using HipHop program provided in Catalyst software and it was used as a query for screening database. Recursive partitioning (RP) model was developed as a filtering system, which was able to classify active and inactive compounds. Eventually, a sequential virtual screening procedure (SQSP) was conducted by applying the common feature pharmacophore and RP model in succession to discover novel potent GSK-3β inhibitors. The final 56 hit compounds were carefully selected considering predicted docking mode in crystal structures. Subsequent enzyme assay for human GSK-3β protein confirmed that three compounds of these hit compounds exhibit micromolar inhibitory activity. Here, we report novel hit compounds and their binding mode in the active site of GSK-3β crystal structure.

Original languageEnglish
Pages (from-to)636-643
Number of pages8
JournalBioorganic and Medicinal Chemistry
Issue number2
Publication statusPublished - 2008 Jan 15

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Novel GSK-3β inhibitors from sequential virtual screening'. Together they form a unique fingerprint.

Cite this